Clinical trial
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients…
NCT00301912 · University of California, San Francisco, Other · Withdrawn
Key facts
| NCT number | NCT00301912 |
|---|---|
| Title | Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
| Official title | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation |
| Enrollment | 0 |
| Start date | Jan 1, 2002 |
| Primary completion | Nov 1, 2007 |
| First posted | Mar 13, 2006 |
| Last update posted | Oct 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: